Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Arq. bras. oftalmol ; 78(5): 295-299, Sep.-Oct. 2015. ilus
Article in English | LILACS | ID: lil-761518

ABSTRACT

ABSTRACTPurpose:To evaluate the effectiveness of topical 1% cyclosporine eye drops diluted in either of the two vehicles-olive and linseed oil-and that of the oils themselves in treating experimentally-induced keratoconjunctivitis sicca (KCS) in rabbits.Methods:KCS was induced in 25 New Zealand rabbits using 1% atropine sulfate eye drops for 7 days before treatment and throughout the treatment period (12 weeks). The rabbits were divided into five groups: one control (C) group without KCS induction and four treatment groups in which KCS was induced and treated topically with olive oil (O), linseed oil (L), cyclosporine in olive oil (CO), and cyclosporine in linseed oil (CL). The animals were evaluated using Schirmer tear test 1 (STT), the fluorescein test (FT), tear-film break-up time (TBUT), the rose bengal test (RBT), and histopathological analysis.Results:Values of STT and TBUT significantly decreased 1 week post-induction (p<0.05) and were similar to initial values after the 4th week of treatment, in all groups. After KCS induction, there was significantly less corneal damage in group L than in group CL, as assessed FT and RBT. Histopathology demonstrated that Groups L and CL presented less edema and corneal congestion. There was no significant difference in the goblet cell density (cells/mm2) between the groups (p=0.147).Conclusion:Cyclosporine diluted in olive oil or linseed oil was effective in the treatment of KCS, although it had better efficacy when diluted in linseed oil. Linseed oil presented better effectiveness, whether associated or not, than olive oil. These results may contribute to the creation of novel topical ophthalmic formulations for KCS treatment in future.


RESUMOObjetivo:Avaliar a eficácia do uso tópico do colírio de ciclosporina 1% em dois veículos, óleo de oliva e linhaça, e dos óleos separados, no tratamento da ceratoconjuntivite seca experimentalmente induzida (KCS) em coelhos.Método:Vinte e cinco coelhos Nova Zelândia foram induzidos para KCS com colírio de sulfato de atropina a 1% por sete dias antes e durante o período de tratamento (12 semanas) e foram divididos em 5 grupos, um grupo controle (C), sem indução de KCS e quatro grupos de tratamento tópico com ciclosporina em óleo de oliva (CO), ciclosporina em óleo de linhaça (CL), óleo de oliva (O) e óleo de linhaça (L). Os animais foram avaliados utilizando o teste lacrimal de Schirmer I (STT), teste de fluoresceína (FT), teste de ruptura do filme lacrimal (TBUT), teste de rosa bengala (RBT) e análise histopatológica.Resultados:Os valores de TBUT e STT diminuíram significativamente uma semana pós-indução da KCS (p<0,05) e foram semelhantes aos valores iniciais após a quarta semana de tratamento, em todos os grupos. Após a indução de KCS, houve menor dano na córnea no grupo L em relação ao grupo CL, quando avaliados FT e RBT. A histopatologia demonstrou que os grupos L e CL apresentaram menos edema e congestão da córnea. Não houve diferença significativa na densidade das células caliciformes (células/mm2) entre os grupos (p=0,147).Conclusão:Ciclosporina diluída em óleo de oliva ou linhaça foi eficiente no tratamento da CCS, porém teve uma melhor eficácia quando diluída no óleo de linhaça. O óleo de linhaça, isoladamente ou associado, apresentou melhor eficácia quando comparado ao óleo de oliva. Estes resultados podem contribuir no futuro com novas formulações oftálmicas tópicas no tratamento da CCS.


Subject(s)
Animals , Male , Rabbits , Cyclosporine/administration & dosage , Immunosuppressive Agents/administration & dosage , Keratoconjunctivitis Sicca/drug therapy , Linseed Oil/administration & dosage , Olive Oil/administration & dosage , Ophthalmic Solutions/administration & dosage , Administration, Ophthalmic , Conjunctiva/drug effects , Conjunctiva/pathology , Cornea/drug effects , Cornea/pathology , Cyclosporine/chemistry , Drug Combinations , Drug Carriers/administration & dosage , Fluorescein , Goblet Cells/drug effects , Immunosuppressive Agents/chemistry , Keratoconjunctivitis Sicca/pathology , Ophthalmic Solutions/chemistry , Reproducibility of Results , Treatment Outcome , Tears
2.
The Korean Journal of Parasitology ; : 251-256, 2014.
Article in English | WPRIM | ID: wpr-207961

ABSTRACT

A novel recombinant Bacille Calmette-Guerin (rBCG) vaccine co-expressed Eimeria tenella rhomboid and cytokine chicken IL-2 (chIL-2) was constructed, and its efficacy against E. tenella challenge was observed. The rhomboid gene of E. tenella and chIL-2 gene were subcloned into integrative expression vector pMV361, producing vaccines rBCG pMV361-rho and pMV361-rho-IL2. Animal experiment via intranasal and subcutaneous route in chickens was carried out to evaluate the immune efficacy of the vaccines. The results indicated that these rBCG vaccines could obviously alleviate cacal lesions and oocyst output. Intranasal immunization with pMV361-rho and pMV361-rho-IL2 elicited better protective immunity against E. tenella than subcutaneous immunization. Splenocytes from chickens immunized with either rBCG pMV361-rho and pMV361-rho-IL2 had increased CD4+ and CD8+ cell production. Our data indicate recombinant BCG is able to impart partial protection against E. tenella challenge and co-expression of cytokine with antigen was an effective strategy to improve vaccine immunity.


Subject(s)
Animals , Adjuvants, Immunologic/genetics , Administration, Intranasal , Antigens, Protozoan/genetics , BCG Vaccine/administration & dosage , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Chickens , Coccidiosis/prevention & control , Disease Models, Animal , Drug Carriers/administration & dosage , Eimeria tenella/genetics , Genetic Vectors , Injections, Subcutaneous , Interleukin-2/genetics , Protozoan Vaccines/administration & dosage , Spleen/immunology , Vaccines, Synthetic/administration & dosage
3.
Acta cir. bras ; 28(4): 233-238, Apr. 2013. ilus, graf, tab
Article in English | LILACS | ID: lil-670247

ABSTRACT

PURPOSE: To evaluate the benefit of using carriers such as the biopolymer gel (hidrogel of polysaccharide of sugarcane molasses) associated with the bone morphogenetic proteins (BMP's) in the repair of critical bone defects in calvaria of Wistar rats. METHODS: Forty-two rats were submitted to a surgical calvaria bone defects. These animals were divided into two experimental groups, positive control group and negative control group. The Group I the calvaria defect was filled up with biopolymer gel, biological membrane, BMP and lyophilized graft. The Group II was treated with biopolymer gel, BMP and lyophilized graft. And the group III (positive control group) was treated with BMP, lyophilized graft and biological membrane. In the negative control group (Group IV) a defect was made in the rat calvaria and the animals were sacrificed immediately after the surgery. The animals of experimental groups and positive control group were slaughtered after subsequent periods of 90 and 180 days. In these periods, the histological analysis and image assessment by cone bean tomographic imaging were obtained. RESULTS: There was highest bone tissue formation with statistically significant results in the groups that associated biopolymer gel and membrane (Group I), followed by the group III (BMP, lyophilized graft and biological membrane). The lower bone formation occurred in the group not using the sugarcane biopolymer gel (Group II). The radiolucent areas of the analyzes of 180 days among the groups studied were respectively, 14.98 mm², 26.65 mm² and 35.81 mm². CONCLUSION: The biopolymer gel showed to be an excellent bone morphogenetic protein carrier, probably by facilitating the controlled release of these proteins in the process of bone repair.


Subject(s)
Animals , Male , Rats , Bone Morphogenetic Proteins/administration & dosage , Bone Regeneration/drug effects , Drug Carriers/administration & dosage , Hydrogels/administration & dosage , Polysaccharides/administration & dosage , Saccharum/chemistry , Biocompatible Materials/administration & dosage , Biopolymers/administration & dosage , Bone Substitutes/administration & dosage , Reproducibility of Results , Time Factors , Treatment Outcome
4.
Salud(i)ciencia (Impresa) ; 19(3): 266-268, ago. 2012.
Article in Spanish | LILACS | ID: lil-686334

ABSTRACT

La metodología utilizada puede contribuir al desarrollo de criterios de equivalencia entre medicamentos multifuente de esta clase por parte de las autoridades sanitarias


Subject(s)
Administration, Oral , Argentina , Drug Carriers/administration & dosage , Drug Carriers/supply & distribution , Drug Carriers/therapeutic use
5.
Arq. bras. oftalmol ; 72(4): 444-450, July-Aug. 2009. ilus, graf, tab
Article in Portuguese | LILACS | ID: lil-528007

ABSTRACT

OBJETIVO: O presente estudo objetivou o desenvolvimento e a avaliação de um sistema biodegradável de liberação de fármacos com característica de liberação prolongada, destinado à administração orbitária de acetato de prednisolona (AP). MÉTODOS: O sistema desenvolvido, na forma de microesferas (MEs) de poli-e-caprolactona (PCL) contendo o AP, foi obtido pelo método de evaporação de solvente. As MEs foram caracterizadas por microscopia eletrônica de varredura (MEV), calorimetria diferencial exploratória (DSC), avaliação do teor de encapsulação e pelo perfil de liberação in vitro. O perfil de liberação in vivo foi avaliado em coelhos após administração peribulbar de uma suspensão aquosa das MEs. A biocompatibilidade local do sistema foi verificada por meio de análise histopatológica da região de implantação. RESULTADOS: Após obtenção das MEs, a análise morfológica por MEV mostrou a viabilidade do método de obtenção do sistema. O teor de AP encapsulado foi de 43 ± 7 por cento e pode ser considerado bastante satisfatório. A caracterização do sistema por DSC, além de confirmar a sua estabilidade, não indicou a existência de interação entre o fármaco e o polímero. O estudo de liberação in vitro indicou que o sistema apresenta perfil de liberação prolongada. O estudo in vivo confirmou o perfil de liberação prolongado do AP a partir das MEs, sugerindo, também, a viabilidade do sistema devido à ausência de toxicidade local. CONCLUSÃO: O conjunto dos resultados obtidos neste trabalho é relevante e credencia o sistema desenvolvido como uma possível alternativa ao tratamento de orbitopatias inflamatórias.


PURPOSE: The present study aimed to evaluate an injectable extended-release formulation of prednisolone acetate (PA) for orbital administration. METHODS: Microspheres (MEs) of poly-e-caprolactone (PCL) containing PA were developed by the method of solvent evaporation. The MEs obtained were characterized by scanning electron microscopy (SEM), differential scanning calorimetry (DSC), encapsulation efficiency and in vitro release profile. The in vivo release profile was evaluated in rabbits after periocular injection of an aqueous suspension of MEs. The local biocompatibility of the system was verified by histopathologic analysis of the deployment region. RESULTS: After MEs preparation, morphological analysis by SEM showed the feasibility of the employed method. The content of PA encapsulated was 43 ± 7 percent and can be considered as satisfactory. The system characterization by DSC technique, in addition to confirm the system stability, did not indicate the existence of interaction between the drug and the polymer. The in vitro release study showed the prolonged-release features of the developed system. Preliminary in vivo study showed the absence of local toxicity and confirmed the prolonged release profile of PA from MEs, suggesting the viability of the developed system for the treatment of orbital inflammatory diseases. CONCLUSION: The results obtained in this work are relevant and accredit the system developed as a possible alternative to the treatment of inflammatory orbitopathy.


Subject(s)
Animals , Female , Rabbits , Anti-Inflammatory Agents/administration & dosage , Biocompatible Materials/chemistry , Prednisolone/analogs & derivatives , Vitreous Body/drug effects , Calorimetry, Differential Scanning , Delayed-Action Preparations/administration & dosage , Drug Carriers/administration & dosage , Materials Testing , Microscopy, Electron, Scanning , Microspheres , Polyesters/administration & dosage , Prednisolone/administration & dosage
6.
Journal of Veterinary Science ; : 65-70, 2001.
Article in English | WPRIM | ID: wpr-72516

ABSTRACT

This study demonstrates that prophylactic effect of plaster and cataplasm contained ketoprofen in adjuvant arthritis therapy by X-ray. Adjuvant arthritis was induced by a single injection of Freund's complete adjuvant. Mature female Sprague-Dawley rats were designated to 3 groups such as nontreated control, plaster-treated (PT) and cataplasm-treated (CT), each of which was composed of ten animals. The PT and the CT groups showed reduced primary paw swelling, but secondary paw swelling was not affected. Bony changes were observed in all regions of the femur and tibia of the nonadjuvant-injected leg and the adjuvant-injected leg. The mean radiographic scores of the PT and the CT groups were significantly lower than those of the control group from day 0 to 7 of the experimental period (p<0.05, p<0.01). The CT rats showed reduced poly-arthritis development than the PT rats. Our results suggest that radiographic assessment of bony changes is more suitable for measuring changes in long bones such as femur or tibia than in vertebrae. The prophylactic effect of CT prominently suppressed edematous swelling and bony changes in arthritic limb compared with PT.


Subject(s)
Animals , Female , Rats , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Arthritis, Experimental/prevention & control , Calcium Sulfate , Drug Carriers/administration & dosage , Excipients/administration & dosage , Freund's Adjuvant , Ketoprofen/administration & dosage , Rats, Sprague-Dawley
7.
Asian Pac J Allergy Immunol ; 1998 Jun-Sep; 16(2-3): 87-91
Article in English | IMSEAR | ID: sea-36963

ABSTRACT

Immunotherapy of allergic diseases is associated with problems of adverse systemic reactions. We have shown earlier that liposome entrapped allergen (LEA) is effective in inducing IgG response and restricting IgE response in immunized mice. This mode of treatment may be more effective and safer if it can prevent anaphylaxis. To determine this feature, mice were administered allergen preparations repeatedly and later challenged with the same allergen. Mice given liposomal preparation showed lower specific IgE response as compared to the mice given free allergen or alum adsorbed allergen of Artemisia scoparia. Specific IgG response was higher in mice immunized with LEA. The mice immunized with liposomal preparation survived whereas others injected with free allergen or alum adsorbed allergen died probably due to anaphylaxis. High levels of histamine were observed in mice injected with free allergen as compared to the mice injected LEA. The increase in plasma histamine level may be the cause of anaphylaxis during allergen challenge. In conclusion, LEA could be used as a safe and effective mode of immunotherapy for allergy diseases, since it reduces plasma histamine levels considerably thereby reducing the chances of anaphylaxis.


Subject(s)
Allergens/administration & dosage , Animals , Artemisia/immunology , Drug Carriers/administration & dosage , Histamine/blood , Immunization/methods , Immunoglobulin E/immunology , Immunoglobulin G/immunology , Immunotherapy/methods , Liposomes/administration & dosage , Mice , Mice, Inbred BALB C , Plants, Medicinal , Pollen/immunology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL